Bristol Myers Squibb Company $BMY Stock Position Lifted by Homestead Advisers Corp

Homestead Advisers Corp grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 0.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 964,189 shares of the biopharmaceutical company’s stock after acquiring an additional 3,700 shares during the quarter. Homestead Advisers Corp’s holdings in Bristol Myers Squibb were worth $44,632,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Magnolia Capital Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 12.9% during the second quarter. Magnolia Capital Advisors LLC now owns 4,491 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 514 shares during the period. Code Waechter LLC grew its position in shares of Bristol Myers Squibb by 57.4% during the 2nd quarter. Code Waechter LLC now owns 12,873 shares of the biopharmaceutical company’s stock valued at $596,000 after buying an additional 4,692 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in Bristol Myers Squibb during the second quarter worth about $972,000. Freestone Capital Holdings LLC lifted its holdings in Bristol Myers Squibb by 24.7% in the second quarter. Freestone Capital Holdings LLC now owns 19,488 shares of the biopharmaceutical company’s stock worth $902,000 after acquiring an additional 3,855 shares during the last quarter. Finally, Wellington Shields Capital Management LLC boosted its stake in Bristol Myers Squibb by 5.2% in the second quarter. Wellington Shields Capital Management LLC now owns 5,486 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 272 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BMY shares. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $57.23.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $45.58 on Wednesday. The stock has a market cap of $92.78 billion, a P/E ratio of 18.38, a P/E/G ratio of 2.23 and a beta of 0.33. The firm’s 50-day simple moving average is $45.28 and its 200 day simple moving average is $46.73. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the firm posted $1.80 EPS. Bristol Myers Squibb’s revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.4%. The ex-dividend date was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is 83.78%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.